Open AccessPossibilities of effective antitumor therapy of patients with chronic lymphocytic leukemia depending on the clinical and laboratory characteristics of the disease
Author(s) -
Yu. V. Shatokhin,
И. В. Снежко,
A. N. Zeltser,
С. В. Морданов,
Е. В. Бурнашева,
L. P. Sizyakinа,
Maria Kharitonova,
E. V. Ryabikina,
О. В. Герасимова,
G. Yu. Nagornaya,
А. А. Мацуга,
L. I. Dyatchina
Publication year - 2020
Publication title -
ûžno-rossijskij žurnal terapevtičeskoj praktiki
Language(s) - English
Resource type - Journals
ISSN - 2712-8156
DOI - 10.21886/2712-8156-2020-1-3-84-90
Subject(s) - medicine , rituximab , ibrutinib , chronic lymphocytic leukemia , regimen , christian ministry , oncology , complete remission , hematology , comorbidity , leukemia , lymphoma , gastroenterology , chemotherapy , philosophy , theology
Purpose : to determine the optimal therapy regimens in patients with CLL, depending on age, comorbidity, prognostic (genetic) factors, clinical picture. Materials and methods: analysis of case histories of 400 patients with CLL observed at the Rostov State Medical University, Ministry of Health of the Russian Federation from 2010 to 2020. Results : Immunochemotherapy according to the FCR and FCR-Lite regimens has shown high efficiency in primary and pre-treated patients in terms of the frequency of achieving complete and partial remissions and achieving progression-free survival. In untreated patients, complete remissions were obtained in 61 (71.7%), partial remissions - in 14 (16.4%); among pre-treated patients, respectively - 40 (20.5%) and 65 (33.8%). Conclusion : combination therapy according to the FCR and FCR-Lite regimens is an affordable and effective method of treatment for most patients with CLL. When the level of leukemic blood cells with 17p13 deletion is less than 15%, rituximab should be used in the first line of immunochemotherapy, and ibrutinib (imbruvica) in case of more than 15%. In mono-regimen, rituximab is effective in supportive - anti-relapse therapy and in the treatment of autoimmune complications.